Cytokine production by peripheral lymphocytes in melanoma

European Cytokine Network

Volumn 16, Issue 1, 2005, Pages 47-55

  Botella Estrada, Rafael ^a,d   Escudero, Marta ^b   O'Connor, José E ^b   Nagore, Eduardo ^a   Fenollosa, Bernardo ^c   Sanmartín, Onofre ^a   Requena, Celia ^a   Guillén, Carlos ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d NONE   (Spain)

Author keywords

Cytokines; Melanoma; Th1; Th2

Indexed keywords

CYTOKINE; FLUORESCEIN ISOTHIOCYANATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY LABELING; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; MELANOMA; PERIPHERAL LYMPHOCYTE; SENTINEL LYMPH NODE; STATISTICAL ANALYSIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

EID: 16444387582     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA. Coffman RL. Two types of murine helper T cell clone. J Immunol 1986; 136: 2348.
2. Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88: 346.
3. Weiss E, Mamelak AJ, La Morgia S, Wang B, Feliciani C, Tulli A, et al. The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. J Am Acad Dermatol 2004; 50: 657.
4. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547.
5. Scott P. IL-12: Initiation cytokine for cell-mediated immunity. Science 1993; 260: 496.
6. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138.
7. Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, et al. Gershenwald, Lee JE. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 2001; 8: 116.
8. Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002; 7: 151.
9. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J Clin Oncol 2001; 19: 3635.
10. Maggi E, Parronchi P, Manetti R, et al. Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 1992; 148: 2142.
11. Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991; 12: 256.
12. Kitani A, Chua K, Nakamura K, Strober W. Activated self-MHC reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J Immunol 2000; 165: 691.
13. Doetze A, Satoguina J. Burchard G, et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol 2000; 12: 623.
14. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111(Suppl): S460.
15. Asadullah K, Sabat R, Wiese A, Docke WD, Volk HD, Sterry W. Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res 1999; 291: 628.
16. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 271.
17. Coyle AJ, Erard F, Bertrand C, Walti S, Pircher H, Le Gross G. Virus-specific CD8+ cells can switch to interleukin 5 production and induce airway eosinophilia. J Exp Med 1995; 181: 1229.
18. Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol Today 1995; 16: 374.
19. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12: 547.
20. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001; 19: 239.
21. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001; 2: 25.
22. Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and downregulates HLA class-I, HLA class-II and ICAM-I molecules. Int J Cancer 1997; 71: 630.
23. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997; 73: 309.
24. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 1634.
25. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683.
26. Yue FY, Dummer R, Geertsen RR, Hofbauer G, Laine E, Manolio S, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class II and ICAM-I molecules. Int J Cancer 1997; 71: 630.
27. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson H, Pisa P, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180: 2371.
28. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 1995; 154: 1280.
29. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans-cell antigen-presenting function by IL10. J Immunol 1993; 151: 2390.
30. Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 1634.
31. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996; 184: 19.
32. Kitani A, Chua K, Nakamura K, Strober W. Activated self-MHC reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J Immunol 2000; 165: 691.
33. Doetze A, Satoguina J, Burchard G, et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r) 1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol 2000; 12: 623.
34. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737.
35. Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, Girolomoni G. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol 2000; 114: 295.
36. Rowbottom AW, Lepper MW, Garland RJ, et al. IL-10 induced CD8 cell proliferation. Immunology 1999; 98: 80.
37. Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998; 160: 3188.
38. Santin AD, Hermonat PL, Ravaggi A, et al. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papilloma virus-specific CD8(+) cytotoxic T lymphocytes. J Virol 2000; 74: 4729.
39. Schwarz MA, Hamilton LD, Tardelli L, Narula SK, Sullivan LM. Stimulation of cytolytic activity by interleukin-10. J Immunother 1994; 16: 95.
40. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy - review of a new approach. Pharmacol Rev 2003; 55: 241.